xinwenbanner-sj.jpg
2022-09-16
China New Technology Pharmaceutical Innovative Enterprises Top 30

Only Innovators Go Steady and Far-reaching

Sing the Horn of Innovation of Chinese Biopharmaceutical Enterprises

Innorna awarded China New Technology Pharmaceutical Innovative Enterprises Top 30


On the afternoon of September 16, 2022, Menet held a press conference on Only Innovators Go Steady and Far-reaching - 2021 China Innovative Bio Pharma Innovative Enterprises Top 100 Lists. This conference invited well-known domestic experts and scholars to interpret policy trends, technological direction and market dynamics of the innovative drug industry, and share perspectives on critical topics in the industry. At the conference, the 2021 China Innovative Bio Pharma Innovative Enterprises Top 100 Lists were released, with senior research experts from Menet explaining the selection methodology for the four sub-lists.

In 2021, 47 innovative drugs in China have passed CDE review, setting a new record high, which means that China's pharmaceutical industry has further enhanced its innovation capability and high-quality development. The process of launching new drugs is also accelerating, and the capability to meet the clinical needs of patients is being strengthened.

To select companies for 2021 China Innovative Bio Pharma Innovative Enterprises Top 100 Lists, Menet organized an expert committee to develop the innovation evaluation indicators into four dimensions, including "investment in innovation", "innovation achievement", "intellectual property" and "innovation-driven", and 11 indicator systems based on Enterprise Innovation Capability Indicator System issued by Ministry of Science and Technology. The committee took into consideration the annual reports of innovative drug companies, CDE data, third-party patent survey agencies and public data to conduct a comprehensive evaluation of innovative drug companies. Referring to the international classification method for biopharmaceutical enterprises, the expert committee divided the list into China Big Pharma Innovation Top 10 List, China Small Molecule Pharmaceutical Innovative Enterprises Top 30 List, and China Antibody Pharmaceutical Innovative Enterprises Top 30 List and China New Technology Pharmaceutical Innovative Enterprises Top 30.

The selection process of the 2021 China Innovative Bio Pharma Innovative Enterprises Top 100 Lists drew attention and participation from industry scholars, new drug R&D institutions, company R&D leaders, entrepreneurs, BD and PR leaders, securities firms and industry professionals. As a result, this selection has created a huge impact with highly positive feedback.

Innorna has committed to innovative development in the field of drugs and vaccines. With its high-quality innovative R&D capabilities, it has been successfully selected into China New Technology Pharmaceutical Innovative Enterprises Top 30 as a sublist of 2021 China Innovative Bio Pharma Innovative Enterprises Top 100 Lists. Under the leadership of Dr. Linxian Li, CEO, the team continues to strive for excellence and explore R&D innovation, which was recognized by the selection committee. As a result, Innorna won the Title of Top 10 enterprise on the China New Technology Pharmaceutical Innovative Enterprises Top 30 list. 

2021 China Innovative Bio Pharma Innovative Enterprises Top 100 Lists is a review and summary of the past achievement of China's pharmaceutical innovation industry, as well as a forecast for the future. The lists will become driving forces for the transformation and upgrading of the industry, reflecting the industry's sincere respect for innovation pioneers, and the great expectations from all biopharmaceutical innovators for the future! Let us ride the east wind of the times and sing the horn of innovation of Chinese biopharmaceutical enterprises. Only those who forge ahead will never stop, and those who are innovators will go steady and far-reaching.